Close Menu
    Facebook X (Twitter) Instagram
    Friday, December 19
    • About Us
    • Write For Us
    • Contact Us
    Facebook X (Twitter) Instagram
    Fortune Herald
    • Business
    • Finance
    • Politics
    • Lifestyle
    • Technology
    • Property
    • Business Guides
      • Guide To Writing a Business Plan UK
      • Guide to Writing a Marketing Campaign Plan
      • Guide to PR Tips for Small Business
      • Guide to Networking Ideas for Small Business
      • Guide to Bounce Rate Google Analyitics
    Fortune Herald
    Home»Press Release»Big win for Zilco – Institute of Physics Business Innovation Award
    Press Release

    Big win for Zilco – Institute of Physics Business Innovation Award

    News TeamBy News Team01/11/2022No Comments3 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Zilico’s innovative diagnostic IED technology, ZedScan has been recognised for it’s notable social impacts.

    The company was recently awarded the prestigious Institute of Physics Business Innovation Award which recognises Zilico’s brilliance in innovation and delivery of significant societal impact through the application of physics.

    The Institute of Physics (IOP) is the professional body and learned society for physics, and the leading body for practising physicists, in the UK and Ireland. With a rich history of supporting business innovation and growth, it is committed to working with ‘physics-based’ businesses, and companies that apply and employ physics and physicists.
    The IOP’s prestigious Business Awards are unique in the UK and Ireland in recognising the significant contribution that physicists and physics make in industry.
    There are three categories of awards – Business Innovation, Business Start-Up and the Lee Lucas Award (for the medical and healthcare sector) – so businesses at any stage of their development are eligible; from start-ups to multi-national corporations.
    The IOP Business Innovation Award specifically recognises and celebrates companies that have excelled in innovation, delivering significant economic and/or societal impact through the application of physics.
    Sameer Kothari, CEO, Zilico, said, “We at Zilico are honoured to win the IOP Business Innovation Award for our innovative diagnostic for cervical cancer. ZedScan has already benefited thousands of patients across the NHS and international hospitals. We are driven to improve cancer diagnostics, especially within women’s health, an area that has been underserved. This recognition by the IOP makes us at Zilico hugely proud and reinvigorates our drive and passion for better outcomes for patients within cancer pathways.”
    Institute of Physics Deputy Chief Executive, Rachel Youngman, said: “The IOP Business Awards recognise and reward the achievements of physics-based businesses at all stages and of all sizes. Whether well-established or a start-up, an SME or corporation, these innovative companies are making significant contributions to the UK and Ireland’s scientific research and development, driving innovation and supporting the economy.
    “All of this year’s winners have creatively applied physics to bring about positive change to individuals, societies or economies, by tackling a new problem or improving on a previous solution, and all are thoroughly deserving of an IOP Business Award.”
    What is ZedScan by Zilico
    ZedScan™ is a unique adjunct diagnostic device which uses EIS (Electrical Impedance Spectroscopy) technology to identify cell changes that cannot always be seen with standard colposcopy.
    Using a single-use EIS sensor, ZedScan takes up to 12 readings from around the cervical transformation zone following the application of acetic acid. EIS works by measuring 7 key cell parameters, at 14 different frequencies, and resulting spectra helps differentiate the different tissue types.
    The readings are processed by an in-built algorithm to quantify the degree of abnormality at each reading site, with the results displayed immediately to support clinical decision making.
    Following a service evaluation of over 200 patients, the Trust found ZedScan increased the detection of high-grade disease (which has the potential to become cancerous) by 26 per cent and helped inform clinical management decisions. The high sensitivity of the ZedScan device also gives clinicians the confidence to discharge women to surveillance or routine screening when no high-grade disease is indicated.
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    News Team

    Related Posts

    Nexus International Delivers $847.9M Revenue While Challenging Gaming’s Largest Operators

    30/10/2025

    Nexus International Targets $5 Billion Milestone in Run-Up to Landmark 2027 IPO

    30/10/2025

    Netherlands Leads the World in Holding Entity Concentration

    18/11/2024
    Leave A Reply Cancel Reply

    Fortune Herald Logo

    Connect with us

    FortuneHerald Logo

    Home

    Terms & Conditions

    Privacy Policy

    Type above and press Enter to search. Press Esc to cancel.